New combo attack on inoperable throat cancer
NCT ID NCT03777813
Summary
This study tested whether adding a new immunotherapy drug (durvalumab) to the standard treatment of chemotherapy and radiation could better control advanced esophageal cancer that cannot be removed by surgery. It involved 112 patients in France who were randomly assigned to receive either the standard treatment alone or the standard treatment plus the immunotherapy drug. The goal was to see if the combination could keep the cancer from growing for a longer period and improve survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGUS CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Rangueil Larrey
Toulouse, France
-
Centre Hospitalier Universitaire
Poitiers, France
-
Centre Oscar Lambret, CLCC UNICANCER
Lille, France
-
Centre Paul Strauss, CLCC UNICANCER
Strasbourg, France
-
Hôpital Haut-Lévêque
Pessac, 33604, France
-
Hôpital Saint Louis, APHP
Paris, 75010, France
-
Iuct, Clcc Unicancer
Toulouse, 31059, France
Conditions
Explore the condition pages connected to this study.